Researchers develop 'three-headed hydra' for anti-cancer activity

By The Science Advisory Board staff writers

October 22, 2021 -- A "three-headed hydra" significantly improves efficacy in targeted protein degradation, according to research published October 21 in Nature Chemical Biology.

Researchers from the University of Dundee in Scotland and Promega developed the trivalent proteolysis-targeting chimeras (PROTACs), which they say opens new possibilities for drug discovery for cancer and other targets.

PROTACs are usually designed with two heads. They are being trialed as candidate medicines against various cancers and are progressing through clinical trials.

A trivalent proteolysis-targeting chimera (PROTAC).
Research by Promega and the University of Dundee shows a "three-headed hydra" significantly improves efficacy in targeted protein degradation. Image courtesy of Promega.

The Dundee/Promega team, however, adopted a three-headed approach, which shows stronger anti-cancer activity in cellular studies at a lower dose and improved pharmacological responses over a wider dose range, according to the study. Researchers designed the trivalent PROTACs by adding an additional protein-binding ligand.

The Dundee/Promega team demonstrated that the new PROTAC works due to the combined effect of avidity (the cumulative strength of multiple interactions between two molecules) and cooperativity (a phenomenon exhibited by molecules with multiple binding sites in which the affinity of the remaining bindings sites is increased after a ligand binds to one of the sites). Avidity and cooperativity, the researchers said, are two important features of protein and small molecule molecular recognition.

Promega unveils Sanger sequencing chemistry system
Promega has introduced ProDye Terminator, a new sequencing system that enables research labs to perform Sanger sequencing on all capillary electrophoresis...
Promega reagent plus Eppendorf cycler enable 15 min PCR amplification
Polymerase chain reaction (PCR) amplification can be completed in as little as 15 minutes with the combined use of Promega's GoTag rapid master mix and...
Promega launches new ADCC bioassay
Promega has partnered with BioIVT to develop a new bioassay to measure the antibody-dependent cellular cytotoxicity (ADCC) of antibodies during drug development...
Promega launches benchtop CE DNA analyzer
Promega has debuted Spectrum Compact CE, a benchtop capillary electrophoresis (CE) instrument.
MilliporeSigma licenses CRISPR tech to Promega
MilliporeSigma announced on December 19 that it has signed a license agreement providing Promega Corp., access to MilliporeSigma's foundational CRISPR...

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter